Search results

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders.

Adiposs is a medtech start-up company, a spin-off of the University of Geneva, developing medical imaging products and technologies.

Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).

Our platform enables efficient, tunable multiplex gene silencing, modulating multiple targets in one construct for superior safety and potency over traditional editing. Its modular design suits various cell and gene engineering applications.

Aptissen is specialized in the development, distribution, and marketing of viscosupplements/orthobiologic solutions and drinkable food supplement in the area of joint health and soft tissue.

Atopia Therapeutics is developing a revolutionary treatment for allergic diseases such as atopic dermatitis, allergic asthma, food allergies and hay fever based on the discovery that a bacterium present in the human stomach produces a protein that protects us from these diseases.

AzureCell is a Swiss regenerative cell therapy company leveraging two decades of pioneering neuroscience and cell‑engineering research at the University of Geneva to advance next‑generation allogeneic cell‑replacement therapies for the brain.

Calliditas is a commercial-stage biopharmaceutical company focused on novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. In 2021, Calliditas acquired Genkyotex, a French‑ and Swiss‑based company specializing in NOX therapies.

Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. We support pharma and biotech companies across the product lifecycle, from clinical through to commercial and operate from sites in North America, Europe, Africa and Asia Pacific.

We want to be strategic collaborator with executive management and empower in-house IR/PR professionals to help you build lasting and mutually beneficial relationships with investors, partners, media, and other stakeholders.

dEEGtal develops AI-driven solutions to enhance EEG analysis, starting with a medical device for epilepsy diagnosis. While focused on clinical applications, we are expanding to offer AI models that provide deeper insights into EEG data for neuroscience, pharma, and industry partners.

FluoSphera has developed human multi-tissue systems that accurately replicate and analyze how a drug interacts with multiple organs to predict systemic response in humans, i.e. the response at the whole body level — ultimately determining clinical success for patients.

EspeRare is an ethical non-profit biotech. It combines pharmaceutical know-how and philanthropic and public investments to bring to life treatments that have been abandoned by the pharmaceutical industry. EspeRare represents an affordable alternative to the high cost innovation of medicines.

Fasteris is the LifeScience brand of Genesupport SA, that offers DNA-sequencing services to LifeScience companies and research. Genesupport SA offers a complete service in the field of human genetics (prenatal, paediatric and adult), delivered by FMH and FAMH specialists.

GliaPharm is a Swiss biotechnology company developing treatments for neurological disorders. The company has developed a proprietary platform and pipeline of molecules targeting brain glial cells to restore brain metabolism deficits in neurological diseases linked to brain metabolism dysfunction.

HekeTiss, a UNIGE/HUG spin-off, enhances lives by pioneering cell-therapy treatments for ulcerative skin conditions. Innovating for a healthier tomorrow.

Infinity Communications works with start-up and growth-stage healthcare companies to deliver insights-driven, strategic communications. We add value by developing content and material to raise your company profile, attract new investors and engage audience groups across the health ecosystem.

iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families.

iQone is a Swiss specialty pharma company for oncology, immunology and rare diseases. We commercialise innovative and biosimilar medicines with 7 marketed and 9 late-stage products. iQone can support partner products directly in the 5 major EU + CH markets, and indirectly in the rest of Europe. iQone Healthca

Labatec is a privately owned Swiss-based pharmaceutical company with more than 50 years of experience in delivering high quality products to the European and Emerging Markets. Covering both the hospital and retail sectors, we have a portfolio of over 65 products and a growing geographic footprint.

Labcorp Central Laboratory Services helps pharmaceutical and biotech companies to develop new drugs by providing a full range of testing services, from preclinical investigations to conducting post-marketing studies. Services include toxicology studies and biostatistical analysis.

Novimmune SA has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018. We now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.

MesenFlow Technologies has developed a service platform to meet the demands of modern drug development. It has been designed to accelerate the development process and provide solutions to common problems associated with species cross-reactivity, animal testing and understanding human disease.

MPC Therapeutics is the leading biotech company developing Mitochondrial Pyruvate Carrier (MPC) targeted therapies. MPC is an extraordinary target that plays a key role in metabolism. We are committed to delivering novel treatments in cancer immunotherapy, kidney diseases and neurodegeneration.

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators.

Olgram develops new drugs to cure immune deficiencies for which there are no satisfactory therapeutic solutions. Our 1st clinical application is immunodepression post traumatic brain injury, affecting 5 million people. We also develop new anti-infectious to cure the chronic bacterial infection.

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections, also active in the treatment of vascular diseases.

Orion Biotechnology is a Swiss/Canadian clinical stage company. Orion is the only company with a novel approach to drug peptide and protein GPCRs. Our platform offers one of the fastest drug discovery solutions in industry to target peptidergic GPCRs. Orion has a strong and diverse pipeline.

We are a small CRO providing highly tailored services to customers with clinical trials and regulatory consulting needs. With expertise in drug, food supplements, medical devices, diagnostics and software, we support you at every stage of product's lifecycle, from preclinical development to market.

QuartzBio SA is a Swiss data driven biomarker discovery and validation company and the trusted partner of companies and institutions for their in-silico biomarker discovery programmes. Leveraging a unique Biomarker Optimisation Software System – BOSS™ – we discover and validate biomarkers.

Release Therapeutics is a preclinical-stage BioMedTech company developing the first cell macroencapsulation technology specifically designed to get therapeutic proteins where they are needed most, in the CNS and beyond.

Solid Drug Development (SDD) is a Strategic and Operational consultancy based in Geneva. The company founded in 2010 is specialized in the development of Biotech and Pharma products.

Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development platform targeting neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).

TheraPPI Bioscience is a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases, and inflammation.